Biosynthesis and Identification of Clenbuterol Metabolites in Urine and In Vitro Microsome Incubation Samples Using UHPLC‐Q‐Exactive Orbitrap Mass Spectrometry: A Comparison Between Human and Bovine Metabolism
Drug Testing and Analysis · 2025
DOI: 10.1002/dta.3942 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Anuar Gómez-Tagle und 5 weiteren Autor:innen. Beteiligte Einrichtung: Organic Chemistry Section, Chemical Sciences Department, Laboratory of Medicinal Green Chemistry, Faculty of Higher Studies Cuautitlan, National Auto…. Hauptthemen laut MEDLINE: Clenbuterol, Microsomes, Liver. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DGAPA UNAM, AGAUR Generalitat de Catalunya, Consell Català de l'Esport (Generalitat de Catalunya, Spain).
Abstract (Originalsprache)
Clenbuterol (Clb) is a β2‐agonist drug included in the list of substances prohibited during and out of competition by the World Anti‐Doping Agency (WADA‐AMA). Several adverse analytical findings have been detected by accredited WADA laboratories, but athletes often claim that results are due to dietary contamination. In this contribution, bovine microsomal incubation and the excretion of bovine and human urinary metabolites of Clb were analyzed and compared using liquid chromatography electrospray Q‐Exactive‐Orbitrap mass spectrometry to determine differences in Clb metabolism. Urine samples were processed by solid‐phase extraction prior to electrospray analysis in both the positive and negative ion modes. MS/MS experiments were obtained by parallel monitoring reaction (PRM) triggered by an inclusion ions list. The strategy for metabolite identification involved the search for typical biotransformation based on accurate mass shifts using diagnostic fragment ions from the parent drug. This approach successfully identified eight metabolites, including a novel N ‐methylated form of Clb, reported here for the first time. Additionally, four metabolites found exclusively in bovine urine offer significant potential for further research aimed at distinguishing unintentional doping.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Organic Chemistry Section, Chemical Sciences Department, Laboratory of Medicinal Green Chemistry, Faculty of Higher Studies Cuautitlan, National Autonomous University of Mexico, Cuautitlán Izcalli, Mexico.
- Catalonian Anti-Doping Laboratory, Hospital del Mar Institute for Medical Research, Barcelona, Spain.
ORCID-Profile: Anuar Gómez-Tagle, Claudia Bressan, Rosa Ventura, Alan Álvarez-Sanchez, Enrique Cardenas-Yong, Benjamín Velasco-Bejarano
Förderung
- DGAPA UNAM
- AGAUR Generalitat de Catalunya
- Consell Català de l'Esport (Generalitat de Catalunya, Spain)
Zitieren
APA
Gómez-Tagle, A., Bressan, C., Ventura, R., Álvarez-Sanchez, A., Cardenas-Yong, E., & Velasco-Bejarano, B. (2025). Biosynthesis and Identification of Clenbuterol Metabolites in Urine and In Vitro Microsome Incubation Samples Using UHPLC‐Q‐Exactive Orbitrap Mass Spectrometry: A Comparison Between Human and Bovine Metabolism. Drug Testing and Analysis. https://doi.org/10.1002/dta.3942
Vancouver
Gómez-Tagle A, Bressan C, Ventura R, Álvarez-Sanchez A, Cardenas-Yong E, Velasco-Bejarano B. Biosynthesis and Identification of Clenbuterol Metabolites in Urine and In Vitro Microsome Incubation Samples Using UHPLC‐Q‐Exactive Orbitrap Mass Spectrometry: A Comparison Between Human and Bovine Metabolism. Drug Testing and Analysis. 2025. doi:10.1002/dta.3942
BibTeX
@article{GmezTagle2025,
author = {Gómez-Tagle, Anuar and Bressan, Claudia and Ventura, Rosa and Álvarez-Sanchez, Alan and Cardenas-Yong, Enrique and Velasco-Bejarano, Benjamín},
title = {Biosynthesis and Identification of Clenbuterol Metabolites in Urine and In Vitro Microsome Incubation Samples Using UHPLC‐Q‐Exactive Orbitrap Mass Spectrometry: A Comparison Between Human and Bovine Metabolism},
journal = {Drug Testing and Analysis},
year = {2025},
doi = {10.1002/dta.3942}
}
EUVIMED